肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 ACR适宜性标准：膀胱癌治疗后监测（更新版）

2021-05-18 美国放射学会 J Am Coll Radiol.2021 May;18(5S):S126-S138.

膀胱癌

2021年5月，美国放射学会(ACR)更新发布了膀胱癌治疗后监测的适宜性标准。尿路上皮癌是第二位常见的癌症，也是与泌尿生殖道癌症致死的原因。膀胱尿路上皮癌治疗后的影像学监测的目的是发现新的或以前未发现

中文标题：

2021 ACR适宜性标准：膀胱癌治疗后监测（更新版）

英文标题：

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update

发布机构：

美国放射学会

发布日期：

2021-05-18

简要介绍：

2021年5月，美国放射学会(ACR)更新发布了膀胱癌治疗后监测的适宜性标准。尿路上皮癌是第二位常见的癌症，也是与泌尿生殖道癌症致死的原因。膀胱尿路上皮癌治疗后的影像学监测的目的是发现新的或以前未发现的尿路上皮癌，鉴别转移性疾病以及评估治疗的并发症。本文主要针对膀胱癌治疗后监测的适宜性影像学检查提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ACR适宜性标准：膀胱癌治疗后监测（更新版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=aaa891c002125003, title=2021 ACR适宜性标准：膀胱癌治疗后监测（更新版）, enTitle=ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update, guiderFrom=J Am Coll Radiol.2021 May;18(5S):S126-S138., authorId=0, author=, summary=2021年5月，美国放射学会(ACR)更新发布了膀胱癌治疗后监测的适宜性标准。尿路上皮癌是第二位常见的癌症，也是与泌尿生殖道癌症致死的原因。膀胱尿路上皮癌治疗后的影像学监测的目的是发现新的或以前未发现, cover=https://img.medsci.cn/202171/1625069691983_2020535.jpg, journalId=0, articlesId=null, associationId=191, associationName=美国放射学会, associationIntro=美国放射学会（American College of Radiology）拥有会员超过34,000名，包括美国放射医师，放射肿瘤学家，物理学家介入医师及核医学医师。其指南按放射检查的方法分类，共十组，每组下包括指南十余篇。同时向NGC提供了近200篇指南。学会拥有《ACR Bulletin》及《JACR》两本官方期刊。, copyright=0, guiderPublishedTime=Tue May 18 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年5月，美国放射学会(ACR)更新发布了膀胱癌治疗后监测的适宜性标准。尿路上皮癌是第二位常见的癌症，也是与泌尿生殖道癌症致死的原因。膀胱尿路上皮癌治疗后的影像学监测的目的是发现新的或以前未发现的尿路上皮癌，鉴别转移性疾病以及评估治疗的并发症。本文主要针对膀胱癌治疗后监测的适宜性影像学检查提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=758, tagName=膀胱癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=758, guiderKeyword=膀胱癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8306, appHits=117, showAppHits=0, pcHits=502, showPcHits=8186, likes=1, shares=8, comments=11, approvalStatus=1, publishedTime=Wed Jun 30 23:55:25 CST 2021, publishedTimeString=2021-05-18, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 30 23:54:59 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Mon Jan 01 12:21:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ACR适宜性标准：膀胱癌治疗后监测（更新版.pdf)])
2021 ACR适宜性标准：膀胱癌治疗后监测（更新版.pdf
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1056615, encodeId=0bb610566155b, content=👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/e74FYPLmKpT4PtNBH5ia1sIyh8vTJuNGlib8NqMulUwNAgPciaUH3t2Lr9kTaaOFdO9fEr7bNAynKyNdTzhwtujZw/132, createdBy=d6a91948909, createdName=雪霁天晴, createdTime=Thu Sep 30 18:40:12 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008218, encodeId=2b0f100821896, content=👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d95438346, createdName=ms1000001198315002, createdTime=Mon Aug 16 07:06:55 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005939, encodeId=ba231005939d4, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/1a7c564710f34a00814401b108f2aca8/049b15f165854d899ab222e8c5ed70b9.jpg, createdBy=68bc5520285, createdName=ms5000000283354824, createdTime=Sun Aug 08 07:11:13 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998315, encodeId=3ccb99831540, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1205546131, createdName=ms1000001126940655, createdTime=Sat Jul 10 23:15:40 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996150, encodeId=fdc3996150e8, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:45:12 CST 2021, time=2021-07-04, status=1, ipAttribution=)]
    2021-09-30 雪霁天晴

    👍🏻

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1056615, encodeId=0bb610566155b, content=👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/e74FYPLmKpT4PtNBH5ia1sIyh8vTJuNGlib8NqMulUwNAgPciaUH3t2Lr9kTaaOFdO9fEr7bNAynKyNdTzhwtujZw/132, createdBy=d6a91948909, createdName=雪霁天晴, createdTime=Thu Sep 30 18:40:12 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008218, encodeId=2b0f100821896, content=👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d95438346, createdName=ms1000001198315002, createdTime=Mon Aug 16 07:06:55 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005939, encodeId=ba231005939d4, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/1a7c564710f34a00814401b108f2aca8/049b15f165854d899ab222e8c5ed70b9.jpg, createdBy=68bc5520285, createdName=ms5000000283354824, createdTime=Sun Aug 08 07:11:13 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998315, encodeId=3ccb99831540, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1205546131, createdName=ms1000001126940655, createdTime=Sat Jul 10 23:15:40 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996150, encodeId=fdc3996150e8, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:45:12 CST 2021, time=2021-07-04, status=1, ipAttribution=)]
    2021-08-16 ms1000001198315002

    👍👍

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1056615, encodeId=0bb610566155b, content=👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/e74FYPLmKpT4PtNBH5ia1sIyh8vTJuNGlib8NqMulUwNAgPciaUH3t2Lr9kTaaOFdO9fEr7bNAynKyNdTzhwtujZw/132, createdBy=d6a91948909, createdName=雪霁天晴, createdTime=Thu Sep 30 18:40:12 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008218, encodeId=2b0f100821896, content=👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d95438346, createdName=ms1000001198315002, createdTime=Mon Aug 16 07:06:55 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005939, encodeId=ba231005939d4, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/1a7c564710f34a00814401b108f2aca8/049b15f165854d899ab222e8c5ed70b9.jpg, createdBy=68bc5520285, createdName=ms5000000283354824, createdTime=Sun Aug 08 07:11:13 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998315, encodeId=3ccb99831540, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1205546131, createdName=ms1000001126940655, createdTime=Sat Jul 10 23:15:40 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996150, encodeId=fdc3996150e8, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:45:12 CST 2021, time=2021-07-04, status=1, ipAttribution=)]
    2021-08-08 ms5000000283354824

    👍

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1056615, encodeId=0bb610566155b, content=👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/e74FYPLmKpT4PtNBH5ia1sIyh8vTJuNGlib8NqMulUwNAgPciaUH3t2Lr9kTaaOFdO9fEr7bNAynKyNdTzhwtujZw/132, createdBy=d6a91948909, createdName=雪霁天晴, createdTime=Thu Sep 30 18:40:12 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008218, encodeId=2b0f100821896, content=👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d95438346, createdName=ms1000001198315002, createdTime=Mon Aug 16 07:06:55 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005939, encodeId=ba231005939d4, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/1a7c564710f34a00814401b108f2aca8/049b15f165854d899ab222e8c5ed70b9.jpg, createdBy=68bc5520285, createdName=ms5000000283354824, createdTime=Sun Aug 08 07:11:13 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998315, encodeId=3ccb99831540, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1205546131, createdName=ms1000001126940655, createdTime=Sat Jul 10 23:15:40 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996150, encodeId=fdc3996150e8, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:45:12 CST 2021, time=2021-07-04, status=1, ipAttribution=)]
    2021-07-10 ms1000001126940655

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1056615, encodeId=0bb610566155b, content=👍🏻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/e74FYPLmKpT4PtNBH5ia1sIyh8vTJuNGlib8NqMulUwNAgPciaUH3t2Lr9kTaaOFdO9fEr7bNAynKyNdTzhwtujZw/132, createdBy=d6a91948909, createdName=雪霁天晴, createdTime=Thu Sep 30 18:40:12 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008218, encodeId=2b0f100821896, content=👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d95438346, createdName=ms1000001198315002, createdTime=Mon Aug 16 07:06:55 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005939, encodeId=ba231005939d4, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/1a7c564710f34a00814401b108f2aca8/049b15f165854d899ab222e8c5ed70b9.jpg, createdBy=68bc5520285, createdName=ms5000000283354824, createdTime=Sun Aug 08 07:11:13 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998315, encodeId=3ccb99831540, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1205546131, createdName=ms1000001126940655, createdTime=Sat Jul 10 23:15:40 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996150, encodeId=fdc3996150e8, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210702/b49b637ce90a455bb1e235f83924397b/5bf685e70c6643ba95249595009efb3d.jpg, createdBy=8ef85539728, createdName=DyralDeng, createdTime=Sun Jul 04 18:45:12 CST 2021, time=2021-07-04, status=1, ipAttribution=)]
    2021-07-04 DyralDeng

    很实用

    0

相关指南

窄带成像在非肌层浸润性膀胱癌诊治中的应用安全共识（2020版）

中国医促会泌尿健康促进分会 · 2021-03-25

2020 JUA临床指实践指南：膀胱癌

日本泌尿外科协会(JUA,Japanese Urological Association) · 2020-06-21

2020 EAU指南：肌层浸润和转移性膀胱癌

欧洲泌尿外科学会(EAU,European Association of Urology) · 2020-04-29

2020 SIGO意见书：老年膀胱癌的管理

国外肿瘤科相关专家小组（统称） · 2020-02-10

拓展阅读

2014 WHO/ICUD共识：膀胱癌筛查，早期诊断和检测的分子标志物

世界卫生组织(WHO,The World Health Organization) · 2014-12-10

2015 关于膀胱癌应用膀胱内BCG免疫治疗专家共识

国外肿瘤科相关专家小组（统称） · 2015-03-24

2016AUA：非肌层浸润性膀胱癌治疗指南

美国泌尿外科学会(AUA,American Urological Association) · 2016-04-14

2016 EAU指南：肌层浸润和转移性膀胱癌（更新版）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2016-06-30

2015 JUA指南：膀胱癌指南的核心内容（更新）  

日本泌尿外科协会(JUA,Japanese Urological Association) · 2016-07-03

2017 AUA/ASCO/ASTRO/SUO指南：非转移性肌浸润性膀胱癌的治疗

美国泌尿外科学会(AUA,American Urological Association) · 2017-04-26